WCLC 2025 - Posters & ePosters-P3.18.77 Efficacy and Safety of Adebrelimab Plus Irinotecan Liposome in ES-SCLC After First-Line Therapy: A Phase II Study (AIPATH)

P3.18.77 Efficacy and Safety of Adebrelimab Plus Irinotecan Liposome in ES-SCLC After First-Line Therapy: A Phase II Study (AIPATH)

Asset Subtitle

Yudong Wang

Meta Tag

Speaker Yudong Wang

Topic Clinical Trials in Progress